Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market is expected to reach USD 566.4 million by 2020. Rising R&D leading to the introduction of new drugs for IVIG and TPO-RA classes is expected to propel growth over the forecast period. In addition, government regulation such as the Orphan Drug Act in the United States with an aim to encourage new product development is projected to fuel growth.
The
industry is characterized by rising demand for combination therapies as they
exhibit higher efficiency as compared to other treatments. Moreover, they are
cost efficient and help curb side effects associated with individual
therapeutic classes. Some of the major combination therapies are dexamethasone
and rituximab, dexamethasone and TPO-RA, IVIG and corticosteroids. Splenectomy,
the procedure to remove spleen is aimed at reducing the amount of anti-platelet
antibodies, is expected to fuel demand.
The
global market for corticosteroid is valued at over USD 125.0 million in 2013. Corticosteroids
are regularly used in idiopathic thrombocytopenic purpura treatment. Since
corticosteroid are considered to be the first line of therapy for patients
suffering from ITP, the usage rates of corticosteroid are very high.
Browse Details of Report @
http://www.grandviewresearch.com/industry-analysis/idiopathic-thrombocytopenic-purpura-itp-therapeutics
TPO-RA
is likely to witness substantial growth, growing at a CAGR of over 9.0% from
2014 to 2020 owing to high response rates exhibited by patients administered
with Eltrombopag and Romiplostim. Moreover, demand for TPO-RA is expected to
increase due to the commercialization of Avatrombopag in 2015. In addition, the
ability of TPO-RA to cater to splenectomized patients witnessing relapses is
expected fuel demand over the next six years.
North
America accounted for a majority share in 2013 due to rising occurrence of
diseases coupled with the presence of high treatment rates, favorable
government initiatives, and funding programs. North America had a share of over
40% of the global ITP market by revenue in 2013 and is expected to witness high
demand over the forecast period.
Europe
accounted for the second largest market share in 2013. This trend is projected
to continue over the forecast period due to high usage rates of products along
with government initiatives granting of special status to orphan drugs factors.
Asia
Pacific is expected to experience substantial growth over the next six years,
owing to the presence of favorable government initiatives, and sophisticated
healthcare infrastructure in Australia and Japan. In addition, the presence of
vast untapped opportunities in emerging markets such as China and India is
expected to propel growth.
Some
of the major players in the industry are and GlaxoSmithKline Plc., Hoffman-L
Roche, Amgen Inc and Grifols Biologicals Inc. The companies make significant
R&D investments aimed at new product development by taking advantage of
incentives offered under the pertinent government regulations.
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment